These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16761908)

  • 1. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Bosanquet N; Yeates A
    Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908
    [No Abstract]   [Full Text] [Related]  

  • 2. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK.
    Zala D; Chan D; McCrone P
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):307-315. PubMed ID: 28612928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.
    Wimo A
    Drugs Aging; 2004; 21(5):279-95. PubMed ID: 15040756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?
    Getsios D; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2007; 25(12):997-1006. PubMed ID: 18047386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London?
    Schneider LS
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):9-13. PubMed ID: 16353164
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.
    Hyde C; Peters J; Bond M; Rogers G; Hoyle M; Anderson R; Jeffreys M; Davis S; Thokala P; Moxham T
    Age Ageing; 2013 Jan; 42(1):14-20. PubMed ID: 23179169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.
    Jönsson L
    Pharmacoeconomics; 2003; 21(14):1025-37. PubMed ID: 13129415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experts disagree over NICE's approach for assessing drugs.
    Hoey R
    Lancet; 2007 Aug; 370(9588):643-4. PubMed ID: 17726791
    [No Abstract]   [Full Text] [Related]  

  • 13. NICE vindicated in UK's High Court.
    Horton R
    Lancet; 2007 Aug; 370(9587):547-8. PubMed ID: 17707735
    [No Abstract]   [Full Text] [Related]  

  • 14. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2002; 20(13):919-42. PubMed ID: 12381243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economics: basic principles and application in mental health.
    Suh GH
    Int Psychogeriatr; 2007 Dec; 19(6):993-1002. PubMed ID: 18161066
    [No Abstract]   [Full Text] [Related]  

  • 17. Utility-weighted measures of quality of life in Alzheimer disease.
    Mador J; Clark M; Crotty M; Hecker J
    Alzheimer Dis Assoc Disord; 2002; 16(3):202. PubMed ID: 12218653
    [No Abstract]   [Full Text] [Related]  

  • 18. [The costs of Alzheimer's disease treatment: the rationale of acetylcholinesterase inhibitors use?].
    Sobów TM; Kłoszewska I
    Psychiatr Pol; 1999; 33(5):761-7. PubMed ID: 10761441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. People with Alzheimer's disease are denied drugs.
    Scott H
    Br J Nurs; 2000 Nov 9-22; 9(20):2120. PubMed ID: 12271179
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.